Lyell Immunopharma, Inc. Quarterly Return On Equity in % from Q4 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Lyell Immunopharma, Inc. quarterly/annual Return On Equity history and growth rate from Q4 2021 to Q3 2024.
  • Lyell Immunopharma, Inc. Return On Equity for the quarter ending September 30, 2024 was -34.6 %, a 39% decline year-over-year.
  • Lyell Immunopharma, Inc. annual Return On Equity for 2023 was -32.7 %, a 51.7% decline from 2022.
  • Lyell Immunopharma, Inc. annual Return On Equity for 2022 was -21.5 %, a 44% increase from 2021.
  • Lyell Immunopharma, Inc. annual Return On Equity for 2021 was -38.4 %, a 145% decline from 2020.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q3 2024 -34.6 -9.72 -39% Jul 1, 2024 Sep 30, 2024
Q2 2024 -33.4 -6.94 -26.3% Apr 1, 2024 Jun 30, 2024
Q1 2024 -33.9 -11.9 -54% Jan 1, 2024 Mar 31, 2024
Q4 2023 -32.7 -11.1 -51.7% Oct 1, 2023 Dec 31, 2023
Q3 2023 -24.9 +4.62 +15.6% Jul 1, 2023 Sep 30, 2023
Q2 2023 -26.4 -0.53 -2.05% Apr 1, 2023 Jun 30, 2023
Q1 2023 -22 +5.56 +20.2% Jan 1, 2023 Mar 31, 2023
Q4 2022 -21.5 +16.9 +44% Oct 1, 2022 Dec 31, 2022
Q3 2022 -29.5 Jul 1, 2022 Sep 30, 2022
Q2 2022 -25.9 Apr 1, 2022 Jun 30, 2022
Q1 2022 -27.6 Jan 1, 2022 Mar 31, 2022
Q4 2021 -38.4 Oct 1, 2021 Dec 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.